The First mRNA Flu Vaccine Approved for Use in Adults Over 50 Marks a Major Breakthrough in Pandemic Preparedness The U.S. Food and Drug Administration (FDA) has approved the first influenza vaccine that utilizes the same mRNA technology as the COVID-19 vaccines, marking a significant advancement in public health. Developed by Moderna, the vaccine, named mFlusiva, is now available for individuals aged 50 and older at select pharmacies ahead of the upcoming flu season. This approval comes after a clinical trial involving 40,000 participants, which demonstrated that the mRNA-based vaccine reduced flu cases by 27% compared to conventional flu shots. The FDA’s decision was based on data from a large-scale study that compared the efficacy of mFlusiva with traditional influenza vaccines. Participants who received the mRNA vaccine experienced a notable decrease in flu-related illnesses, with the results highlighting the potential of mRNA technology to revolutionize vaccine development. Conventional flu vaccines, which are typically produced using chicken eggs, have historically been less effective due to the challenge of predicting the dominant flu strains for the upcoming season. This mismatch often leads to reduced efficacy, with conventional vaccines offering protection ranging from 40% to 60% annually. Moderna’s mFlusiva, however, bypasses this limitation by delivering genetic instructions for producing viral proteins directly to the body’s cells. This approach allows the immune system to recognize and combat the flu virus more effectively. According to immunologist Hanover Matz, a coauthor of the study, the mRNA vaccine generates a stronger and longer-lasting immune response.#us_food_and_drug_administration #moderna #mflusiva #hanover_matz #flu_season
